Safety and efficacy of intravenous bimagrumab in inclusion body myositis

Lancet published the latest results to Bimagrumab from Novartis in the RESILIENT study.

Between Sept 26, 2013, and Jan 6, 2016, 251 participants were enrolled to the study, of whom 63 were assigned to each bimagrumab group and 62 were allocated to the placebo group.

For more Details visit Lancet

Clinical Trials
Bimagrumab

News about Myositis